Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
December 29, 2016
Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
December 21, 2016
Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
December 21, 2016
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
December 20, 2016
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
December 13, 2016
Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint
December 9, 2016
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
December 8, 2016
Bristol-Myers Squibb Announces Dividend Increase
December 6, 2016
Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
December 5, 2016
Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
December 5, 2016
Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study
November 30, 2016
Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
November 22, 2016
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
November 16, 2016
Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program
November 16, 2016
Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
November 14, 2016
Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
November 12, 2016
Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer
November 12, 2016
Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
November 12, 2016
Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma
November 10, 2016
Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
November 10, 2016
Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
November 10, 2016
Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research
November 10, 2016
Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016
November 10, 2016
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
November 10, 2016
Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study
November 9, 2016
Bristol-Myers Squibb to Take Part in Stifel 2016 Health Care Conference
November 9, 2016
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors
November 3, 2016
Bristol-Myers Squibb to Present New Data at the 58th Annual Meeting & Exposition of the American Society of Hematology Demonstrating Research Advancements in Immuno-Oncology and Across Multiple Blood Cancers
November 2, 2016
New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations
November 1, 2016
Bristol-Myers Squibb to Take Part in Credit Suisse 2016 Health Care Conference
October 31, 2016
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
October 28, 2016
Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade
October 27, 2016
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 25, 2016
New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients
October 24, 2016
Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research
October 21, 2016
U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer
October 21, 2016
Bristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27
October 17, 2016
Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot
October 14, 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
October 9, 2016
Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer
October 9, 2016
Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study
October 9, 2016
Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
October 9, 2016
Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study
October 9, 2016
Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer
October 8, 2016
Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer
October 8, 2016
Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study
October 3, 2016
New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach
September 27, 2016
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
September 22, 2016
Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference
September 20, 2016
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer
September 20, 2016
Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
September 7, 2016
Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
September 7, 2016
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
September 7, 2016
Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
September 6, 2016
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
September 6, 2016
European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
August 31, 2016
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
August 23, 2016
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
August 5, 2016
Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
August 3, 2016
Bristol-Myers Squibb Announces Dividend
July 28, 2016
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 26, 2016
Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer
July 25, 2016
Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
July 25, 2016
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
July 25, 2016
CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU
July 20, 2016
Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis
July 18, 2016
Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
July 5, 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
June 30, 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
June 27, 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
June 24, 2016
Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola
June 20, 2016
Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer
June 10, 2016
New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
June 9, 2016
Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
June 9, 2016
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association
June 8, 2016
Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
June 7, 2016
Bristol-Myers Squibb Announces Dividend
June 7, 2016
Bristol-Myers Squibb and MD Anderson Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer
June 6, 2016
Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma Continues to Validate Bristol-Myers Squibb’s Immuno-Oncology Combination Approach
June 5, 2016
Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting
June 5, 2016
First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer
June 5, 2016
Promising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study CheckMate -032
June 4, 2016
Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Study CheckMate -012
May 31, 2016
Bristol-Myers Squibb to Take Part in Goldman Sachs 37th Annual Global Health Care Conference
May 23, 2016
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 18, 2016
Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer
May 18, 2016
Breadth and Depth of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 17, 2016
Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
May 17, 2016
Bristol-Myers Squibb Opens Expanded Biologics Facility
May 11, 2016
Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy
May 11, 2016
European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma
May 5, 2016
Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-Oncology Research through Ready. Raise. Rise. Campaign
April 28, 2016
Bristol-Myers Squibb Reports First Quarter Financial Results
April 27, 2016
Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
April 25, 2016
Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
April 19, 2016
First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
April 17, 2016
First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma
April 14, 2016
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
April 6, 2016
European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma
April 6, 2016
European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
April 1, 2016
Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
April 1, 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma
March 30, 2016
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
March 24, 2016
Bristol-Myers Squibb to Present at William Blair Conference, Cancer Immunotherapy: A Long-Awaited Reality
March 23, 2016
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
March 16, 2016
Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo® (nivolumab) as Monotherapy and in Combination with Yervoy® (ipilimumab) at the AACR 2016 Annual Meeting
March 15, 2016
Bristol-Myers Squibb to Announce Results for First Quarter 2016 on April 28
March 9, 2016
Bristol-Myers Squibb to Present at Barclays Global Health Care Conference
March 7, 2016
Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies
March 3, 2016
Bristol-Myers Squibb Announces Dividend
March 3, 2016
Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors
February 29, 2016
Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference
February 26, 2016
Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma
February 22, 2016
Bristol-Myers Squibb Completes Previously Announced Sale of its HIV R&D Portfolio to ViiV Healthcare
February 22, 2016
Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients
February 16, 2016
Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
February 5, 2016
U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
February 3, 2016
Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference
February 1, 2016
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities
February 1, 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
January 29, 2016
Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy
January 28, 2016
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV
January 28, 2016
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
January 28, 2016
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results
January 25, 2016
REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1
January 23, 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1
January 5, 2016
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference